EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Emapalumab Treatment in Patients With Rheumatologic Disease–Associated Hemophagocytic Lymphohistiocytosis in the United States: A Retrospective Medical Chart Review Study

Shanmuganathan Chandrakasan, Carl E Allen, Deepika Bhatla, John Carter, May Chien, Robert Cooper, Lauren Draper, Olive S Eckstein, Rabi Hanna, J Allyson Hays, Michelle L Hermiston, Ashley P Hinson und 18 weitere

Arthritis & Rheumatology · 2025

DOI: 10.1002/art.42985 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2025. Verfasst von Shanmuganathan Chandrakasan und 29 weiteren Autor:innen. Beteiligte Einrichtung: Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic, Antibodies, Monoclonal, Humanized, Arthritis, Juvenile, Rheumatic Diseases. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Swedish Orphan Biovitrum.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Rheumatologic disease–associated hemophagocytic lymphohistiocytosis (HLH), a rare, life‐threatening, systemic hyperinflammatory syndrome, occurs as a complication of underlying rheumatologic disease. Real‐world evidence is lacking on emapalumab, a fully human monoclonal antibody that neutralizes the proinflammatory cytokine interferon‐γ, approved for treating patients with primary HLH.

Methods

REAL‐HLH, a retrospective medical chart review study conducted across 33 US hospitals, assessed real‐world treatment patterns and outcomes in patients with HLH treated with one or more dose of emapalumab between November 20, 2018, and October 31, 2021. Data are presented for the subset of patients with rheumatologic disease–associated HLH.

Results

Fifteen of 105 patients (14.3%) had rheumatologic disease–associated HLH. Of these, nine (60.0%) had systemic juvenile idiopathic arthritis, and one (6.7%) had adult‐onset Still disease. Median (range) age at HLH diagnosis was 5 (0.9–39) years. Most patients (9 of 15; 60.0%) initiated emapalumab in an intensive care unit. Emapalumab was most frequently initiated for treating refractory or recurrent (10 of 15; 66.7%) disease. Most patients received HLH‐related therapies before (10 of 15; 66.7%) and concurrently with (15 of 15; 100.0%) emapalumab. Emapalumab‐containing regimens stabilized or achieved physician‐determined normalization of most laboratory parameters, including absolute neutrophil count and absolute lymphocyte count (13 of 14; 92.9%), chemokine ligand 9 (9 of 11; 81.8%), and platelets and alanine transaminase (11 of 14; 78.6%), and reduced glucocorticoid dose by 80%. Overall survival and 12‐month survival probability from emapalumab initiation were 86.7%.

Conclusion

Emapalumab‐containing regimens stabilized or normalized most key laboratory parameters, reduced glucocorticoid dose, and were associated with low disease‐related mortality, thereby demonstrating potential benefits in patients with rheumatologic disease–associated HLH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphohistiocytosis, HemophagocyticAntibodies, Monoclonal, HumanizedArthritis, JuvenileRheumatic DiseasesAntibodies, MonoclonalHumansRetrospective StudiesMaleFemaleAdultUnited StatesChildAdolescentYoung AdultChild, PreschoolInfantStill's Disease, Adult-OnsetTreatment OutcomeAntibodies, Neutralizing

Substanzen

Antibodies, Monoclonal, HumanizedEmapalumabAntibodies, MonoclonalAntibodies, Neutralizing

Autor:innen und Institutionen

  • Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia.
  • Baylor College of Medicine, Houston, Texas.
  • Saint Louis University, Saint Louis, Missouri.
  • Oregon Health and Science University, Portland.
  • Lucile Packard Children's Hospital at Stanford University, Palo Alto, California.
  • Bellflower Medical Center, Bellflower, California.

Förderung

  • Swedish Orphan Biovitrum

Zitieren

APA

Chandrakasan, S., Allen, C. E., Bhatla, D., Carter, J., Chien, M., Cooper, R., Draper, L., Eckstein, O. S., Hanna, R., Hays, J. A., Hermiston, M. L., Hinson, A. P., Hobday, P. M., Isakoff, M. S., Jordan, M. B., Leiding, J. W., Modica, R., Nakano, T. A., Oladapo, A., …, & REAL‐HLH investigators (2025). Emapalumab Treatment in Patients With Rheumatologic Disease–Associated Hemophagocytic Lymphohistiocytosis in the United States: A Retrospective Medical Chart Review Study. Arthritis & Rheumatology. https://doi.org/10.1002/art.42985

Vancouver

Chandrakasan S, Allen CE, Bhatla D, Carter J, Chien M, Cooper R, et al. Emapalumab Treatment in Patients With Rheumatologic Disease–Associated Hemophagocytic Lymphohistiocytosis in the United States: A Retrospective Medical Chart Review Study. Arthritis & Rheumatology. 2025. doi:10.1002/art.42985

BibTeX
@article{Chandrakasan2025,
  author = {Chandrakasan, Shanmuganathan and Allen, Carl E and Bhatla, Deepika and Carter, John and Chien, May and Cooper, Robert and Draper, Lauren and Eckstein, Olive S and Hanna, Rabi and Hays, J Allyson and Hermiston, Michelle L and Hinson, Ashley P and Hobday, Patricia M and Isakoff, Michael S and Jordan, Michael B and Leiding, Jennifer W and Modica, Renee and Nakano, Taizo A and Oladapo, Abiola and Patel, Sachit A and Pednekar, Priti and Riskalla, Mona and Sarangi, Susmita N and Satwani, Prakash and Tandra, Anand and Walkovich, Kelly J and Yee, John D and Zoref-Lorenz, Adi and Behrens, Edward M and REAL‐HLH investigators, REAL‐HLH investigators},
  title = {Emapalumab Treatment in Patients With Rheumatologic Disease–Associated Hemophagocytic Lymphohistiocytosis in the United States: A Retrospective Medical Chart Review Study},
  journal = {Arthritis & Rheumatology},
  year = {2025},
  doi = {10.1002/art.42985}
}
Kostenlos starten →